PRRT2 and COVID-19: The PKC inhibitor ruboxistaurin (LY-333531) has demonstrated anti-NETotic activity against NETs induced by lipopolysaccharide (LPS) by neutrophils isolated from hospitalized patients with COVID-19 (44).